Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: Role of interleukin-2 and cyclic AMP signaling pathways

Journal of Cellular Biochemistry

Volumn 89, Issue 5, 2003, Pages 975-991

  Butler, Jared J ^a   Mader, Jamie S ^a   Watson, Carrie L ^a   Zhang, Hong ^a   Blay, Jonathan ^a   Hoskin, David W ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Adenosine; Co stimulation; Cyclic AMP; Interleukin 2; T lymphocytes

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENYLATE CYCLASE; CD2 ANTIGEN; CD28 ANTIGEN; CELL PROTEIN; COFORMYCIN; CYCLIC AMP; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADENOSINE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD2; ANTIGENS, CD28; ANTIGENS, CD3; CAFFEINE; CELL CYCLE; CYCLIC AMP; FEMALE; FLAVINS; FORSKOLIN; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; PHENETHYLAMINES; RECEPTORS, INTERLEUKIN-2; RECEPTORS, PURINERGIC P1; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TYROSINE;

EID: 0043270551     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10562     Document Type: Article

References (51)

1. Abbracchio MP, Brambilla R, Ceruti S, Kim HO, von Lubitz DK, Jacobson KA, Cattabeni F. 1995. G protein-dependent activation of phospholipase C by adenosine A3 receptors in rat brain. Mol Pharmacol 48:1038-1045.
2. Abraham D, Bou-Gharios G, Tulip G, Sumner H, Olsen I. 1994. Regulation of CD2-mediated heterotypic interactions of murine T lymphocytes. Cell Immunol 156:342-356.
3. Alberola-Ila J, Places L, De La Calle O, Romerao M, Yague J, Gallart T, Vives J, Lozano F. 1991. Stimulation through the TCR/CD3 complex up-regulates the CD2 surface expression on human T lymphocytes. J Immunol 146:1085-1092.
4. Andersson J, Nagy S, Groth C-G, Andersson U. 1992. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 75:136-142.
5. Antonysamy MA, Moticka EJ, Ramkumar V. 1995. Adenosine acts as an endogenous modulator of IL-2-dependent proliferation of cytotoxic T lymphocytes. J Immunol 155:2813-2821.
6. Benbernou N, Esnault S, Shin HC, Fekkar H, Guenounou M. 1997. Differential regulation of IFN-gamma, IL-10, and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway. Immunology 91:361-368.
7. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F. 1998. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160:5669-5675.
8. Berger SA, Rowan K, Morrison HD, Ziltener HJ. 1996. Identification of a bacterial inhibitor of protein kinases. Mechanism and role in host cell invasion. J Biol Chem 271:23431-23437.
9. Blay J, White TD, Hoskin DW. 1997. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602-2605.
10. Butler JJ, Cochran J, Ward N, Hoskin DW. 2002. Activation-induced expression of cell surface CD28 on mouse T lymphocytes is inhibited by cyclosporine A. Am J Transplant 2:215-222.
11. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A, Blay JY. 1997. The host-tumor immune conflict: From immunosuppression to resistance and destruction. Immunol Today 18:493-497.
12. + T cell response. Crit Rev Immunol 17:89-119.
13. Dasmahapatra KS, Hill HZ, Dasmahapatra A, Suarez S. 1986. Evaluation of adenosine deaminase activity in patients with head and neck cancer. J Surg Res 40:368-373.
14. Dong RP, Kamcoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C. 1996. Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 156:1349-1355.
15. Ganss R, Hanahan D. 1998. Tumor microenvironment can restrict the effectiveness of activated anti-tumor lymphocytes. Cancer Res 58:4673-4681.
16. Green JM, Karpitskiy V, Kimzey SL, Shaw AS. 2000. Coordinate regulation of T cell activation by CD2 and CD28. J Immunol 164:3591-3595.
17. Hammond JR. 1991. Comparative pharmacology of the nitrobenzylthioguanosine-sensitive and -resistant nucleoside transport mechanisms of Ehrlich ascites tumor cells. J Pharmacol Exp Ther 259:799-807.
18. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: Expression and function. J Exp Med 180:631-640.
19. Hoskin DW, Butler JJ, Drapeau D, Haeryfar SMM, Blay J. 2002. Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer 99:386-395.
20. Huang S, Apasov S, Koshiba M, Sitkovsky M. 1997. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90:1600-1610.
21. Kaiser M, Brooks-Kaiser J, Fitzpatrick L, Bleackley RC, Hoskin DW. 1993. Cytotoxic cell proteinase gene expression and cytolytic activity by anti-CD3-activated cytotoxic T lymphocytes is sensitive to cyclosporin A but is not dependent on interleukin-2 synthesis. J Leukoc Biol 54:458-464.
22. Kato K, Koyanagi M, Okada H, Takanashi T, Wong YW, Williams AF, Okumura K, Yagita H. 1992. CD48 is a counter-receptor for mouse CD2 and in involved in T cell activation. J Exp Med 176:1241-1249.
23. Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjöberg J, Pisa P, Petersson M. 1999. Tumor-induced immune dysfunction. Cancer Immunol Immunother 48:353-362.
24. 2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem 272:25881-25889.
25. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 165:779-785.
26. Lenschow DJ, Walunas TL, Bluestone JA. 1996. CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233-258.
27. MacKenzie WM, Hoskin DW, Blay J. 1994. Adenosine inhibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor. Cancer Res 54:3521-3526.
28. MacKenzie WM, Hoskin DW, Blay J. 2002. Adenosine suppresses α4β7 integrin-mediated adhesion of T lymphocytes to colon adenocarcinoma cells. Exp Cell Res 276:90-100.
29. Makrigiannis AP, Musgrave BM, Hoskin DW. 1999. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody. J Leukoc Biol 66:792-802.
30. Marone G, Petracca R, Vigorita S, Casolaro V. 1990. Adenosine receptors of human leukocytes-II. Characterization of an inhibitory P-site. Biochem Pharmacol 40:963-1973.
31. Minkowski MD, Bandeira A. 1985. Different functional subsets of cultured murine T cells express characteristic levels of adenosine deaminase activity. Cell Immunol 95:380-391.
32. Minkowski MD, Castellazzi M, Buttin G. 1984. Lack of adenosine deaminase activity in cultured murine cytotoxic T lymphocytes. J Immunol 133:52-58.
33. 2B adenosine receptors in human lymphocytes: Their role in T cell activation. J Cell Sci 112:492-502.
34. Moingeon P, Chang HC, Sayre PH, Clayton LK, Alcover A, Gardner P, Reinherz EL. 1989. The structural biology of CD2. Immunol Rev 111:111-144.
35. Murray JL, Perez-Soler R, bywaters D, Hersh EM. 1986. Decreased adenosine deaminase (ADA) and 5′ nucleotidase (5NT) activity in peripheral blood T cells in Hodgkin disease. Am J Hematol 21:57-66.
36. Musgrave BL, Watson CL, Hoskin DW. 2003. CD2-CD48 interactions promote cytotoxic T lymphocyte induction and function: Anti-CD2 and anti-CD48 antibodies impair cytokine synthesis, proliferation, target recognition/ adhesion, and cytotoxicity. J Interferon Cytokine Res 23:67-82.
37. Nel AE. 2002. T-cell activation through the antigen receptor. Part 1: Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immunol 109:758-770.
38. Pawson T. 2002. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 38(Suppl 5):S3-S10.
39. Ralevic V, Burnstock G. 1998. Receptors for purines and pyrimidines. Pharmacol Rev 50:413-492.
40. Rothermel JD, Jastorff B, Botelho LH. 1984. Inhibition of glucagon-induced glycogenolysis in isolated rat hepatocytes by the Rp diastereomer of adenosine cyclic 3′,5′-phosphorothioate. J Biol Chem 259:8151-8155.
41. Skalhegg BS, Landmark BF, Doskeland SO, Hansson V, Lea T, Jahnsen T. 1992. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J Biol Chem 267:15707-15714.
42. Tam RC, Phan UT, Milovanovic T, Pai B, Lim C, Bard J, He L. 1997. Oligonucleotide-mediated inhibition of CD28 expression induces human T cell hyporesponsiveness and manifests impaired contact hypersensitivity in mice. J Immunol 158:200-208.
43. Tamir A, Granot Y, Isakov N. 1996. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase, and c-Jun N-terminal kinase. J Immunol 157:1514-1522.
44. Tesch AM, MacDonald MH, Kollias-Baker C, Benton HP. 2002. Chondrocytes respond to adenosine via A2 receptors and activity is potentiated by an adenosine deaminase inhibitor and a phosphodiesterase inhibitor. Osteoarthritis Cart 10:34-43.
45. + mature thymocytes. J Immunol 144:1646-1653.
46. Vánky F, Nagy N, Hising C, Sjövall K, Larson B, Klein E. 1997. Human ex vivo carcinoma cells produce transforming growth factor β and thereby can inhibit lymphocyte functions in vitro. Cancer Immunol Immunother 43:317-323.
47. Watts TH, DeBenedette MA. 1999. T cell co-stimulatory molecules other than CD28. Curr Opin Immunol 11:286-293.
48. Whiteside TL, Parmiani G. 1994. Tumor-infiltrating lymphocytes: Their phenotype, functions, and clinical use. Cancer Immunol Immunother 39:15-21.
49. Williams BA, Manzer A, Blay J, Hoskin DW. 1997. Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells. Biochem Biophys Res Commun 231:264-269.
50. Xu H, Littman DR. 1995. The kinase-dependent function of Lck in T-cell activation requires an intact site for tyrosine autophosphorylation. Ann NY Acad Sci 766:99-116.
51. Zhang YQ, Joost van Neerven RJ, Van Gool SW, Coorevits L, de Boer M, Ceuppens JL. 1997. B7-CD28 interaction is a late acting co-stimulatory signal for human T cell responses. Int Immunol 9:1095-1102.